Curium's Lantheus deal is worth up to $114.50 a share. Only $102.50 of it is a price.

On 3 August, Curium agreed to acquire Lantheus for $102.50 per share in cash, plus non-transferable contingent value rights worth up to $12.00 more. The companies size the transaction at up to roughly $8.0 billion, with closing expected in the first half of 2027.

Three days later, Lantheus reported second-quarter results, suspended its full-year 2026 guidance and skipped its earnings call. Normal housekeeping for a company under agreement. It also happens to be the last clean look at the business whose sales decide whether that extra $12.00 ever arrives.

Read the two together and you get the most useful skill in deal coverage: telling a price from a bet.

What a contingent value right actually is

A CVR is a contractual promise from the buyer to pay more later if specified things happen. It is not stock. It is not escrow. It is an unsecured IOU whose value depends on a business you no longer own, run by people you did not hire.

This one is non-transferable, which is the detail most retail coverage skips. The 8-K is blunt about it: the CVRs are "non-tradeable contractual rights only", not transferable except in limited circumstances, not certificated, not registered with the SEC and not listed for trading. There is no ticker, no bid, no quote to check your position against. You take the $102.50 at closing, and then you hold a piece of paper until 2030 tells you whether it was worth anything.

The eight milestones, and where the money sits

The 8-K lists each tranche, and the measurement period matters as much as the number:

Franchise	Sales threshold	Payment per share	Measured in
Global prostate cancer diagnostics	> $950M	$1.00	FY ending 31 Dec 2030
Global prostate cancer diagnostics	> $1,100M	$1.00	FY ending 31 Dec 2030
Global prostate cancer diagnostics	> $1,200M	$2.00	FY ending 31 Dec 2030
Global prostate cancer diagnostics	> $1,500M	$2.00	FY ending 31 Dec 2030
Global prostate cancer diagnostics	> $1,750M	$2.00	FY ending 31 Dec 2030
Global neurology diagnostics	> $300M	$2.00	Any of FY2028, 2029 or 2030
Global neurology diagnostics	> $350M	$1.00	Any of FY2028, 2029 or 2030
Global DEFINITY business	> $400M	$1.00	FY ending 31 Dec 2030

These are single-year sales tests, not cumulative ones. Six of the eight turn on what a franchise sells in calendar 2030 alone — one twelve-month window, four years out. The neurology pair is the only one with more than one chance at bat.

Note the concentration too. Two thirds of the contingent value rides on a single franchise, prostate cancer diagnostics, and the largest tranches sit at the highest thresholds. That is a normal way to structure a CVR: the buyer pays most for the outcome it is least willing to underwrite up front.

Is $950 million a stretch?

Lantheus published the yardstick itself on 6 August. PYLARIFY, its PSMA imaging agent and the bulk of the prostate diagnostics franchise, did $240.4 million in the quarter, down 4.1% year over year. Four quarters at that rate is roughly $960 million.

So the cheapest tranche in the table asks a franchise that is currently shrinking to hold approximately its present run rate — and to still be holding it in 2030, since that is the only year the test is run. The top tranche asks it to grow toward twice that. Between them sit three more steps, each requiring the decline to reverse and then keep going.

The other two franchises land differently. DEFINITY did $88.3 million in the quarter and grew 5.2%, an annualised rate already inside sight of its $400 million threshold. That tranche is worth $1.00. Neuraceq did $39.6 million against a neurology threshold of $300 million, and that one pays $2.00.

Read the pattern: the milestone most likely to hit is worth the least, and the milestones worth the most need the hardest growth from the weakest starting point. That is the design working as intended, and it is why "up to $114.50" and "$102.50" are not close to the same statement.

What the 38% premium is measured against

The deal materials quote a premium of 38% to Lantheus's unaffected 60-day volume-weighted average price and 29% to the 30-day. Volume-weighted average price is just the average trade price over a window, weighted by how much stock changed hands at each level.

"Unaffected" is the load-bearing word. It means the price before deal reports moved the stock. Measuring against it is a defensible convention: a buyer should not get credit for a premium over a price its own leaked negotiations created. It also means the 38% is not the premium to where shares traded the day before the announcement — the same slide puts the premium to Lantheus's closing price on 21 May 2026 at 21%. Both facts are true at once, and only one of them describes what a holder who bought last month is being handed.

What the filing answers, and what it does not

The press release is thin. The 8-K is not, and three things retail coverage still calls unknown are written down in it:

• What counts inside each franchise. The 8-K defines them. "Global Prostate Cancer Diagnostics" is PYLARIFY, PYLARIFY TruVu and LNTH-2401, any radiodiagnostic containing piflufolastat or RM2, and future PSMA-targeted agents derived from them. Neurology is Neuraceq, MK-6240, NAV-4694 and LNTH-2620 plus their derivatives. So the pipeline counts toward the thresholds, which makes the run-rate arithmetic above a floor rather than the whole picture.
• What the sales number actually is. Not net revenue as reported. The tests run on "Aggregate Adjusted Sales", which adds royalties, sublicense income, clinical collaboration revenue and DEFINITY kit revenue to product sales, and nets out only discounts, rebates, credits and allowances — explicitly not sales commissions.
• What efforts the buyer owes. There is a covenant: Curium must use "Commercially Reasonable Efforts" to achieve each milestone and must not act, or fail to act, "with the purpose or intent of avoiding or impeding the obligation to pay." That is a real constraint and a soft one — it bars deliberate sabotage, not the ordinary underinvestment that produces the same result.

Two gaps survive:

• How "Commercially Reasonable Efforts" is defined. The term is defined in the CVR agreement itself, filed as an exhibit to the merger agreement. The definition is where this covenant is won or lost, and a summary is not the definition.
• Antitrust. Two radiopharmaceutical competitors are combining, and the timeline implies close to a year of review. The financing carries no conditions, but regulatory clearance is a different question entirely.

What to watch

• The CVR agreement filed as an exhibit to the merger agreement, and the proxy statement to follow. The franchises are already defined; what is not is how "Commercially Reasonable Efforts" is measured. That definition, not the press release, is where the CVR's real value is set.
• PYLARIFY's trajectory over the next two quarters, and whether the newly approved TruVu formulation, due commercially in the fourth quarter, stabilises it. The first tranche turns on that line.
• Antitrust review, and whether any divestiture is required — divesting into the prostate franchise would cut directly into the CVR thresholds.
• Any appraisal or shareholder litigation over the split between certain cash and contingent value.

The portable lesson is a habit, not a view on this deal. When a headline says "up to," find the floor first and treat everything above it as a separate, unpriced instrument you are being asked to accept in place of money. Sometimes that instrument pays. When it does not, the answer to "what did the deal pay?" was always the first number.

This is analysis, not investment advice. It describes what has been disclosed and what has not, and does not recommend any position in any security.